.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Harvard Business School
Healthtrust
Fuji
Baxter
Chinese Patent Office
Boehringer Ingelheim
US Army
Moodys
Federal Trade Commission

Generated: September 24, 2017

DrugPatentWatch Database Preview

KERYDIN Drug Profile

« Back to Dashboard

What is the patent landscape for Kerydin, and what generic Kerydin alternatives are available?

Kerydin is a drug marketed by Anacor Pharms Inc and is included in one NDA. There are five patents protecting this drug.

This drug has sixty-four patent family members in twenty countries.

The generic ingredient in KERYDIN is tavaborole. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tavaborole profile page.

Summary for Tradename: KERYDIN

Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list35
Patent Applications: see list44
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:KERYDIN at DailyMed

Pharmacology for Tradename: KERYDIN

Ingredient-typeBoron Compounds
Drug ClassOxaborole Antifungal
Mechanism of ActionProtein Synthesis Inhibitors
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Anacor Pharms Inc
KERYDIN
tavaborole
SOLUTION;TOPICAL204427-001Jul 7, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Anacor Pharms Inc
KERYDIN
tavaborole
SOLUTION;TOPICAL204427-001Jul 7, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Anacor Pharms Inc
KERYDIN
tavaborole
SOLUTION;TOPICAL204427-001Jul 7, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Anacor Pharms Inc
KERYDIN
tavaborole
SOLUTION;TOPICAL204427-001Jul 7, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Anacor Pharms Inc
KERYDIN
tavaborole
SOLUTION;TOPICAL204427-001Jul 7, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Anacor Pharms Inc
KERYDIN
tavaborole
SOLUTION;TOPICAL204427-001Jul 7, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: KERYDIN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,767,657Boron-containing small molecules► Subscribe
8,722,917Boron-containing small molecules► Subscribe
8,440,642Boron-containing small molecules► Subscribe
8,115,026Boron-containing small molecules► Subscribe
8,039,451Boron-containing small molecules► Subscribe
9,353,133Boron-containing small molecules► Subscribe
8,889,656Boron-containing small molecules► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: KERYDIN

Country Document Number Estimated Expiration
Australia2006333527► Subscribe
Japan2013018778► Subscribe
China102532180► Subscribe
Denmark2343304► Subscribe
Russian Federation2414906► Subscribe
Japan2010248265► Subscribe
South Korea20100105869► Subscribe
SloveniaEP2343304► Subscribe
Japan2015117243► Subscribe
Japan6109140► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Cerilliant
Argus Health
Chubb
US Department of Justice
Healthtrust
Harvard Business School
Baxter
Mallinckrodt
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot